Breast cancer adjuvant endocrine therapy

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Adjuvant endocrine therapy with tamoxifen significantly reduces mortality in early-stage, hormone receptor-positive breast cancer for pre- and postmenopausal women.
• Aromatase inhibitors (AIs) demonstrate clear benefits in adjuvant endocrine regimens for postmenopausal women.

Purpose of the Study:

• To review the current landscape of adjuvant endocrine therapy for early-stage hormone receptor-positive breast cancer.
• To discuss the benefits and side effect profiles of tamoxifen versus aromatase inhibitors.
• To highlight ongoing research directions for optimizing endocrine therapy and overcoming resistance.

Main Methods:

• Review of recent large clinical trials and ongoing research in adjuvant endocrine therapy for breast cancer.
• Comparison of efficacy, safety profiles, and side effects of tamoxifen and aromatase inhibitors.

Main Results:

• Aromatase inhibitors (AIs) offer benefits for postmenopausal women, with lower risks of endometrial carcinoma and thromboembolic events compared to tamoxifen.
• AIs are associated with myalgias, arthralgias, and reduced bone mineral density.
• Tamoxifen remains the standard of care for premenopausal women; AI monotherapy is contraindicated.

Conclusions:

• Adjuvant endocrine therapy is crucial for improving survival in early-stage hormone receptor-positive breast cancer.
• Further research is needed to determine optimal sequencing, duration, and AI agents, and to identify predictive biomarkers.
• Investigating ovarian function suppression alongside tamoxifen or AIs is an active area of exploration.